The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Programme (NVP) in September 2010. The impact of PCV10 vaccination against invasive pneumococcal disease (IPD) in vaccine-eligible children has been high, possibly due to cross-protection against PCV10-related serotypes (serotypes in the same serogroups as the PCV10 types) in addition to protection against PCV10 serotypes. We evaluated the long-term impact of PCV10 vaccination against IPD in vaccine-eligible and older, unvaccinated children six years after
2 updated data about the overall and indirect long-term impact of PCV10 vaccination against IPD 25 among vaccine-eligible and unvaccinated older children, with a special focus on cross-protection 26 against the vaccine-related serotypes.
27

Methods
28
The vaccination programme 29 PCV10 was introduced into the NVP in September 2010. Children born on or after June 1, 2010, 30 are eligible for vaccination with a 2+1 schedule (primary series at 3 and 5 months and a booster 31 dose at 12 months of age). There was no catch-up vaccination at PCV10 introduction. In the birth 32 cohort of 2012, the uptake of at least one dose of PCV10 was estimated at 94% based on data in the 33 National Vaccination Register. 14 
34
In 2009-2011, the effectiveness of PCV10 against vaccine-type IPD was investigated in a nation- 35 wide FinIP vaccine trial, in which over 30,000 children born 2008 through May 2010 were 36 vaccinated with PCV10. 15 During the FinIP trial, the PCV10 vaccine coverage varied regionally 37 from 0 to 60%. Prior to the FinIP trial and the introduction of PCV10 into the NVP, no 38 pneumococcal conjugate or polysaccharide vaccines were routinely used for healthy children and 39 adults, and the vaccine uptake was estimated to be less than 2%. 40 Influenza vaccine was introduced into the NVP in the beginning of the influenza season 2007/2008 41 for children aged 6 to 36 months. The uptake of this age group has been estimated to vary between 4 children who were enrolled in the FinIP trial in years 2009-2010 were excluded from the analysis.
70
The follow-up period started at 3 months of age (the first scheduled vaccination dose) and lasted 71 until the end of December 2016 for the target cohort and December 2008 for the reference cohort.
72
The follow-up thus included children from 3 to 78 months of age.
73
To assess time trends in the age-specific risk of 19A IPD, age-specific cumulative hazards were 74 calculated for the target and reference cohorts.
75
Indirect impact of PCV10 vaccination in unvaccinated children 76 To estimate the indirect impact of PCV10 vaccination against IPD, the relative reduction in the 77 incidence of IPD for each serotype group was estimated by comparison of unvaccinated cohorts of 78 older children after and before PCV10 introduction (Figure 1, (reference) cohort. The follow-up included children from 19 to 131 months of age.
84
Statistical methods
85
Comparison of IPD incidence rates was performed by using Poisson regression. Vaccine impact 86 was defined as (1-incidence rate ratio)*100%, comparing the target and reference cohorts. Absolute 87 rate reductions and the corresponding confidence intervals were calculated from the parameter 88 estimates with the delta method. No adjustments were made for comorbidities or influenza Supplement Table 1 .
119
There were six breakthrough cases defined as vaccine-type IPD more than two weeks after 120 administration of the booster dose at 12 months among the fully vaccinated children (received all 3 121 doses). The causative serotypes were 19F (2 cases), 23F (2 cases), 6B and 14. No vaccine-type IPD 122 cases occurred between two primary doses and a booster dose.
123
Indirect impact of PCV10 vaccination in unvaccinated children
124 Table 2 presents the relative and absolute rate reductions in IPD incidence, based on the 125 unvaccinated target cohort of older children (19-131 months of age) during 2012-2016 and its 126 reference cohort in the years 2006-2010. The incidence of PCV10 serotype IPD decreased by 58% 127 (95% CI 37 to 73%) from 5.9 cases in the reference cohort to 2.5 cases per 100,000 person-years in 128 the target cohort, and the incidence of all IPD by 33% (95% CI 8 to 52%) from 7.3 to 4.8 per reported after PCV10 vaccination in all unvaccinated age-groups. 13 In our study, the number of 160 cases of the older unvaccinated children was too small to assess indirect protection against 6A.
161
However, 6A is not a replacing serotype among older children and adults in Finland in IPD 25 or in 162 carriage in children 26 suggesting some degree of indirect impact.
163
In contrast to 6A and our earlier observation based on a three-year follow-up post introduction 6 , we 164 observed no significant effect of PCV10 against 19A IPD. There were, however, differences by age 165 and calendar time in 19A disease between the cohorts, as the cases of the vaccine-eligible cohort 166 tended to be older and occur more often towards the end of the follow-up than those of the reference 167 cohort. One explanation could be the increasing infection pressure from 19A, also seen in adult age 168 groups 2012-2013 onwards 25 ; another speculation is that the 19F component in PCV10 induces 169 initial cross-protection which wanes with age thus rendering vaccinated children susceptible again 170 to 19A in lack of specific 19A immunity. The small number of cases and year-to-year variability 171 make firm conclusions difficult.
172
After PCV7 introduction in the USA and several countries in Europe, 19A carriage and the 173 incidence of 19A IPD increased rapidly among children targeted to vaccination and also in older 174 age groups. 3, 4, 7, 11, 22 Our results are in contrast with the 3-to 4-fold increases of 19A IPD post-PCV7 175 in the USA in children 11 , although the increases in adults have been similar. 11, 25 In the US, the 176 increase in 19A disease was mainly due to the increase in antimicrobial-resistant clonal complex 177 (CC) 320 and a concurrent decrease in antimicrobial-susceptible CC199, suggesting that antibiotic 178 selection pressure could have contributed to the 19A emergence 27,28 . In Finland, the outpatient 179 antimicrobial use is lower than in USA 29 , and also lower than the average for all European Union In our first evaluation three years after PCV10 implementation in Finland, the 19A IPD incidence The strengths of the current study setting include high data completeness (≈80% of isolates in years 199 2002-2008 were available for serotyping, and ≈100% after that) and a well-established and 200 consistent reporting in a population-based nationwide surveillance system. The personal identity 201 code allowed linkage between different registers to find vaccination histories and health statuses for 202 the IPD cases.
203
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